(Q37748477)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20458330%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

review article

1 reference

title

Treatment of metastatic renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20458330%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20458330%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

4

Pierre I Karakiewicz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20458330%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1

Maxine Sun

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20458330%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

3

Paul Perrotte

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20458330%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

11 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20458330%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

published in

Nature Reviews Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20458330%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20458330%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

327-338

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20458330%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20458330%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrurol.2010.57

2 February 2020

exact match

0 references

cites work

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Population-based Assessment of Survival After Cytoreductive Nephrectomy Versus No Surgery in Patients With Metastatic Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

A Population-based Analysis of the Rate of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Sequential therapy in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Immunotherapy for advanced renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

The in vitro generation and sustained culture of nude mouse cytolytic T-lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

31 March 2020

Interleukin-2 toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Interferon-alpha in malignant and viral diseases. A review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Immunotherapy of renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Nephrectomy for metastatic renal cell carcinoma: Indiana University experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Role of cytoreductive nephrectomy in renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Renal-cell carcinoma--molecular pathways and therapies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Development and validation of a scale to measure disease-related symptoms of kidney cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Sunitinib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Sunitinib efficacy against advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Portal hypertension and liver surgery following selective internal radiation therapy with 90Yttrium microspheres.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Treatment outcome for metastatic papillary renal cell carcinoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Sequential sorafenib and sunitinib for renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Sunitinib for treatment of advanced renal cell cancer: primary tumor response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Novel therapeutics for metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Predicting Outcomes in Prostate Cancer: How Many More Nomograms Do We Need?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.57

Metastatic renal cell carcinoma: recent advances in the targeted therapy era.

31 March 2020

1 reference

12 December 2020

The use of interferon in renal cell carcinoma

1 reference

12 December 2020

Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).

1 reference

12 December 2020

Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement

1 reference

12 December 2020

Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.

1 reference

12 December 2020

Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.

1 reference

12 December 2020

Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.

1 reference

12 December 2020

Interleukin-2, autotolerance, and autoimmunity

1 reference

12 December 2020

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

1 reference

12 December 2020

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

12 December 2020

Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein

1 reference

12 December 2020

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Cytoreductive surgery for stage IV renal cell carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2010.57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20458330%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference